Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic EBV-specific DC-CTL
- Development stage
- Preclinical
- Lead developer
- Peking University First Hospital
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic EBV-specific DC-CTL (dendritic cell-activated cytotoxic T lymphocytes) is an adoptive cellular immunotherapy being developed for the treatment of Epstein-Barr virus (EBV)-associated lymphoproliferative diseases (EBV-LPD). The therapy involves generating EBV-specific cytotoxic T lymphocytes (CTLs) from healthy related donors (or HLA-haploidentical donors) by stimulating them with donor-derived dendritic cells (DCs) loaded with EBV-specific antigen peptides. These mature, antigen-primed CTLs are then expanded ex vivo and infused into the patient, where they specifically target and eliminate EBV-infected cells presenting viral latency proteins (such as LMP1, LMP2, and EBNA1) on their surface, thereby restoring anti-viral and anti-tumor immune surveillance without inducing significant graft-versus-host disease (GVHD).
- Other names
- allogeneic EBV-specific DC-CTL infusionallogeneic EBV-specific DC-CTLsallogeneic EBV-specific dendritic cell-cytotoxic T lymphocytesallogeneic Epstein-Barr virus-specific dendritic cell-cytotoxic T lymphocytesrelated-donor allogeneic Epstein-Barr virus-specific dendritic cell-cytotoxic T lymphocyte
02
Targets
pMHC (Peptide-MHC complex family)pMHC-I (Peptide–MHC class I complex)Epstein-Barr virus antigen peptide-human leukocyte antigen complexesEpstein-Barr virus latent membrane protein 1 peptide-human leukocyte antigen complex
Beyond the preview
Go deeper on allogeneic EBV-specific DC-CTL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic EBV-specific DC-CTL.